Significantly Positive Phase 2 Results Eliminate Need for High Dose Cohort Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTCQB:KALTF) (the “Company” or “Kalytera”) today announced that interim results from the Company’s Phase 2...
Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced it has initiated ReDUX4, a Phase 2b clinical trial of losmapimod in...
On Target Laboratories Inc., a privately held biotechnology company that is developing tumor-targeted fluorescent imaging agents to improve cancer surgery, announced today that it has completed its Phase 2, multi-center, open-label clinical trial for OTL38 in the...
Trial with once a day oral dosing to be conducted in 232 patients with moderate to severe ulcerative colitis at more than 150 sites in over 15 countries Published 9-month interim results of ongoing Phase 2a maintenance study ABX464-102 confirmed durability of safety...
Knopp Biosciences LLC today announced the start of Phase 2 dose-ranging clinical trial in moderate-to-severe eosinophilic asthma. Recruitment in the trial is underway and the first patient has been enrolled. The Company anticipates reporting top-line data from this...
ViewRay, Inc. (VRAY) announced today the acceptance of publication by the International Journal of Radiation Oncology, Biology and Physics of the first prospective clinical trial of MR-guided radiation therapy (MRgRT) in patients with localized prostate cancer. This...
Email
Text